New Agent Tested to Attack Blood Vessels that Feed Tumors

University of Pennsylvania Cancer Center
Ultima Vez Modificado: 18 de mayo del 1998

Share article


Tumor growth beyond the size of a pinpoint is dependent on the formation of new blood vessels, a process called angiogenesis. "Anti-angiogenesis" agents are being explored as a way to inhibit new blood vessel formation, and thus starve tumors of the blood supply they need to grow and spread.

The agent was engineered to identify and attack the vascular endothelial growth factor (VEGF) protein produced by the new tumor blood vessels. In animal models, inhibition of VEGF by this anti-VEGF monoclonal antibody inhibits tumor growth. This phase I study assessed the safety of the compound on 25 adult patients with metastatic cancer. One patient with renal cell cancer showed a 39 percent reduction in tumor size, and 13 patients had stable disease ten weeks into treatment. Importantly, patients in the trial experienced very few side-effects from the treatment, and had no bleeding problems. The evidence for the safety of this approach allows for future clinical testing for efficacy.

[ Original Abstract ]



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información